More than 40 women representing HIV prevention advocates, reproductive health service providers, and women living with HIV from Kenya, South Africa, Rwanda, Uganda and Zimbabwe met to review and discuss the existing data on hormonal contraceptive use and HIV risk.
African Women’s Civil Society Consultation on HIV Risk and Hormonal Contraceptives
PrEP Primer (Chinese)
This document, developed by 2012 AVAC Advocacy Fellow Cai Lingping, provides background information on pre-exposure prophylaxis, reviews the evidence base and planned trials, and discusses key issues for Chinese advocates. It explores implementation challenges and the funding landscape for continued research.
Press Statement from Kenya AIDS Civil Society AIDS Groups Cheer First Major New Commitment by Presidential Candidate
This press release from a coalition of Kenyan civil society groups celebrates a success in an election-year campaign led by 2013 AVAC Advocacy Fellow Maureen Milanga to secure commitments to good HIV policy by political candidates. The pledge by Prime Minister Raila Odinga committed his administration, if elected, to provide universal access to antiretroviral therapy and to spend 15 percent of the national budget on healthcare.
Online CHAIN MSM Survey: Willingness and influencing factors for usage of PrEP among MSM
This study of 760 men who have sex with men in China, conducted by 2013 AVAC Advocacy Fellow Cai Lingping, finds high acceptability of pre-exposure prophylaxis. The survey also assessed how well informed respondents were about PrEP and examined factors that would make them more or less willing to take it.
HIV Civil Society Recommendations for Kenya’s New Health Secretary and Global Fund Application
This letter, written by a civil society coalition co-led by 2013 AVAC Advocacy Fellow Maureen Milanga, summarizes concerns and demands related to Kenya’s 2013 application to the Global Fund. The letter was sent during the Global Fund’s transition to its New Funding Model and includes guidance to the Government of Kenya on how to navigate the new system to secure support for ambitious treatment scale-up in the wake of new WHO treatment guidelines.
Ugandan Service Provider Perspectives on the WHO Recommendation on Hormonal Contraceptives and HIV Risk
This abstract poster, developed by 2012 AVAC Advocacy Fellow Lydia Mulwanyi-Mukombe and her Host, Lillian Mworeko, describes key findings from consultations with Uganda service providers. It reports how providers were planning to use the new WHO guidance and makes recommendations for how to protect and inform women in light of the potential HIV risk associated with hormonal contraceptive use.
Community Involvement in HIV Prevention Research: Experiences and perceptions of communities participating in the MDP 301 microbicide trial in Masaka, Uganda
This case study by 2010 AVAC Advocacy Fellow Richard Hasunira assesses the community engagement efforts of the Masaka trial site through interviews with participants, trial staff, and other stakeholders. It highlights success that other trials should replicate and lessons learned from shortcomings.
MUWRP/AVAC: Biomedical HIV Prevention Research Stakeholder Training Resource
This manual, developed by 2010 AVAC Advocacy Fellow Jauhara Nanyondo, is an HIV prevention literacy tool intended to improve reporting by Ugandan media. It covers background information on HIV, provides an overview of existing and emerging prevention options, and discusses clinical research process and ethics.
2005 AVAC Report: AIDS Vaccines at the Crossroads
This year’s Report offers recommendations for the field in general, the Global HIV Vaccine Enterprise, policy makers, researchers and communities. Some of these recommendations will be familiar because AVAC has made them before, and they are reiterated because it is AVAC’s belief that they are still needed. The Report also provides an update on tenofovir pre-exposure prophylaxis research.
2004 AVAC Report: AIDS Vaccine Trials: Getting the Global House in Order
This year’s Report focuses on how the field is readying itself for the road ahead. Several chapters address different aspects of “readiness”—a term that means different things to different people, but that is at the heart of the AIDS vaccine advocacy agenda today.